Latest Hospitality News

Enlitic has secured a US$806,000 contract to migrate 10.6 million medical imaging studies for University of Michigan Health-Sparrow. The project also gives its Ensight platform a first active integration with Sectra’s enterprise imaging environment.

EMVision Medical Devices has received a $4.3 million R&D tax refund, adding non-dilutive funding as it progresses clinical work on its emu™ and First Responder devices. The cash arrives against a last reported cash balance of $17.1 million and $4.6 million in remaining grant funding at 30 June 2026.

Nexsen has proposed a 50:50 joint venture with FlashDx Shenzhen to develop and commercialise an enhanced molecular Group B Streptococcus test, using an existing CE-marked platform as its starting point. The proposed venture could shorten Nexsen’s path into hospital and intrapartum testing across Asia-Pacific, but the term sheet remains non-binding and regulatory work is still ahead.

HealthCo Healthcare and Wellness REIT (ASX: HCW) reported a $49.7 million FY26 statutory loss, suspended distributions and received an unmodified audit opinion that nevertheless highlighted a material uncertainty over its ability to continue as a going concern. The key unresolved issue is the transfer of 10 Healthscope hospitals to alternative operators.

Ramsay Health Care delivered stronger FY26 earnings, a higher fully franked dividend and improved Funding Group leverage as it prepares to separate Ramsay Santé. The proposed demerger remains conditional, but the company has set a clear timetable for the next phase of its portfolio reshaping.

Nexsen has paused its StrepSure clinical programme after an interim review identified performance improvements needed before a US FDA submission, pushing the target timetable back by roughly one quarter. Its shares were then suspended pending an announcement about a potentially material contract for an additional device.

Microba shareholders would own about 67% of an enlarged Genetic Signatures under a proposed all-scrip merger valued at approximately A$51 million. The deal combines roughly A$29.6 million of FY2026 revenue and identifies up to A$3 million in potential annual cost synergies, but remains subject to a long list of approvals.

EVT delivered growth across hotels, cinemas and Thredbo in FY2026 while outlining an approximately $500 million non-core property divestment programme. The group is also reviewing its structure as it redirects capital towards asset-light hotel expansion and considers potential special dividends.

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.

CMS has finalised higher Medicare inpatient reimbursement for EBR Systems’ WiSE System, lifting base payment rates by up to 93% from 1 October 2026. The change improves the commercial payment pathway, although its financial impact will depend on procedure volumes, hospital adoption and NTAP eligibility.

Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.

Austco Healthcare delivered record FY26 revenue and statutory profit, with stronger margins, cash generation and a modest recovery in contracted orders entering the new financial year. The company is pairing that momentum with further reseller consolidation, including the $2.88 million acquisition of Medical Communications Systems.